> News that scientists had found a way to program skin cells to act like embryonic stem cells has failed to shake the clinical trial plans of the leading developers in the field. Report [1]
> Shares of Delcath Systems surged on the news that the FDA approved resumption of clinical trials of its perfusion delivery technology. Report [2]
> At 44, Pharmion co-founder and CEO Pat Mahaffy says he plans to start a new biotech company after Celgene completes its buyout. Report [3]
> Exelixis has sold an 80 percent stake in Artemis Pharmaceuticals to Taconic Farms for $20 million. Artemis develops and markets genetically engineered mouse models and engineered mouse embryonic stem cells as genetic model systems for use in drug discovery or academic research. Report [4]
> Cerus is spinning off its immunotherapy business. Report [5]
> The FDA has extended its action date on Spectrum Pharmaceuticals' ISO-Vorin or levofolinic acid or LFA for injection NDA by 60 days. Report [6]
And Finally… There's new evidence that the best way to stay mentally tough is to give your brain a regular workout. Release [7]
Links:
[1] http://www.newsday.com/technology/wire/sns-ap-stem-cells-biotech,0,5436516.story
[2] http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-21121597.htm
[3] http://www.bizjournals.com/denver/stories/2007/11/19/daily27.html
[4] http://money.cnn.com/news/newsfeeds/articles/prnewswire/AQTU07120112007-1.htm
[5] http://www.fiercebiotech.com/press-releases/press-release-unless-thing-has-rotating-bristles-teeth-i-m-gonna-be-little-suspicious
[6] http://www.rttnews.com/sp/breakingnews.asp?date=11/20/2007&item=128
[7] http://www.sciencedaily.com/releases/2007/11/071119100331.htm